SCHEDULE 13G/A: Perceptive Advisors Maintains Significant 7.3% Stake in Iovance Biotherapeutics
Beneficial Ownership Report
Perceptive Advisors LLC, along with Joseph Edelman and Perceptive Life Sciences Master Fund, Ltd., has reported a continued beneficial ownership of 7.3% in Iovance Biotherapeutics, Inc., holding 22,112,266 shares as of December 31, 2024.
Summary
- Perceptive Advisors LLC, Joseph Edelman, and Perceptive Life Sciences Master Fund, Ltd. (collectively, the "Reporting Persons") have filed an Amendment No. 2 to Schedule 13G regarding their beneficial ownership in Iovance Biotherapeutics, Inc.
- As of December 31, 2024, the Reporting Persons collectively beneficially own 22,112,266 shares of Iovance Biotherapeutics, Inc. Common Stock.
- This ownership represents 7.3% of the Issuer's outstanding Common Stock.
- The percentage is calculated based on 304,780,790 outstanding shares, as reported in Iovance Biotherapeutics' Quarterly Report on Form 10-Q filed on November 7, 2024.
- Perceptive Life Sciences Master Fund, Ltd. directly holds all 22,112,266 shares.
- Perceptive Advisors LLC serves as the investment manager to the Master Fund, and Joseph Edelman is the managing member of Perceptive Advisors LLC, granting them shared voting and dispositive power over the shares.
- The securities were not acquired or held for the purpose of changing or influencing the control of the issuer.
Sentiment
Score: 6
Explanation: The filing is largely neutral as it's a routine disclosure of beneficial ownership. However, the continued significant stake by a prominent life sciences investor like Perceptive Advisors can be viewed as a positive signal of confidence in the company's long-term prospects, hence a slightly positive score.
Positives
- A significant institutional investor, Perceptive Advisors, maintains a substantial 7.3% stake, indicating continued confidence in Iovance Biotherapeutics.
Industry Context
This filing indicates continued significant institutional investment in the biotechnology sector, specifically in Iovance Biotherapeutics, a company focused on cell therapies. Large stakes by specialized life sciences funds like Perceptive Advisors are common in the biotech industry, reflecting long-term investment strategies in high-growth potential companies.
Stakeholder Impact
- Shareholders: Confirmation of a significant institutional investor's continued stake may provide a degree of stability and confidence.
Key Dates
| Date | Description |
|---|---|
| 2024-11-07 | Date of Issuer's Quarterly Report on Form 10-Q, which reported 304,780,790 outstanding shares used for percentage calculation. |
| 2024-12-31 | Date of event which requires filing of this statement (beneficial ownership as of year-end). |
| 2025-02-14 | Date of filing of this Schedule 13G Amendment No. 2. |
Keywords
Iovance Biotherapeutics, Perceptive Advisors, Joseph Edelman, Perceptive Life Sciences Master Fund, Beneficial Ownership, SEC Filing, Schedule 13G, Common Stock, Biotechnology, Institutional Investor, Shareholding
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.